Article
No evidence of a role for activating CDK2 mutations in melanoma.
Melanoma research - 1 Aug 2001
Walker G, Hayward N
Abstract excerpt
Inactivation of p16INK4a and/or activation of cyclin-dependent kinase-4 (CDK4) are strongly associated with both susceptibility and progression in melanoma. Activating CDK4 mutations prevent the binding and inhibition of CDK4 by p16INK4a. A second, more indirect role for CDK4 is in late G1, where it may sequester the inhibitors p27KIP1 or p21CIP1 away from CDK2, and in doing so upregulate the CDK2 activity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.